Navigation Links
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
Date:7/7/2009

REDWOOD CITY, Calif., July 7 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the appointment of Sunil Patel to the position of Senior Vice President, Corporate Development. In this new position, Mr. Patel will have primary responsibility for corporate business development activities, reporting directly to Paul Hastings, OncoMed's President and Chief Executive Officer.

"We are pleased to welcome Sunil to the OncoMed management team. His track record in strategic deal making, particularly in the field of oncology drug discovery and development, make him a great addition," said Mr. Hastings. "Sunil's wealth of corporate development expertise will be an important asset for OncoMed as we discover novel anti-cancer stem cell therapeutics and advance our product candidates into clinical development."

Mr. Patel brings more than 15 years of biopharmaceuticals industry experience to his new role at OncoMed. He joins OncoMed from BiPar Sciences where as Vice President, Corporate Development and Marketing he led the sale of that company to Sanofi-Aventis in April of this year. Previously, he held senior corporate development, marketing, and strategy positions with Allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences. Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his career, he was a researcher at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and his master's degree in Molecular Bioengineering/Biotechnology at the University of Washington.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed's lead candidate, OMP-21M18 is currently in Phase I clinical trials. Privately-held, OncoMed's investors include: Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures, Delphi Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company's website: www.oncomed.com.


'/>"/>
SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoMed Pharmaceuticals Completes Series B Financing
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)...  BioElectronics Corporation (OTC Pink: BIEL), the maker ... it is responding to a notice of an ... Exchange Commission posted on the agency website.  ... Board of BioElectronics Corporation and the Edward and ... Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... has an active R&D program for the development of ... Group has a unique research and development center in ... Bio Control products. Stockton has a ... regulatory guidelines, and is active in more than 35 counties ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/5/2016)... ATCC, the premier global biological materials resource ... and life science researchers that are working to address ... CDC website . --> CDC ... a single-stranded RNA virus of the Flaviviridae family, genus ... Chikungunya Viruses. Zika virus is transmitted to humans primarily ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 25, 2016   Unisys Corporation (NYSE: UIS ) ... Kennedy (JFK) International Airport, New York City , ... imposters attempting to enter the United States ... pilot testing of the system at Dulles last ... at JFK during January 2016. --> pilot testing ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
Breaking Biology News(10 mins):